DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy.

Academic Article

Abstract

  • PURPOSE: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts. PROCEDURES: Groups 1-4 of nude mice bearing human breast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining. RESULTS: DCE-MRI measured a significant K (trans) change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K (trans) changes followed quadratic polynomial curves. CONCLUSION: DCE-MRI detected significantly lower K (trans) levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.
  • Published In

    Keywords

  • Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Bevacizumab, Breast Neoplasms, Female, Humans, Magnetic Resonance Imaging, Mice, Mice, Nude, Receptors, TNF-Related Apoptosis-Inducing Ligand, Transplantation, Heterologous
  • Digital Object Identifier (doi)

    Pubmed Id

  • 18931552
  • Author List

  • Kim H; Folks KD; Guo L; Stockard CR; Fineberg NS; Grizzle WE; George JF; Buchsbaum DJ; Morgan DE; Zinn KR
  • Start Page

  • 94
  • End Page

  • 103
  • Volume

  • 13
  • Issue

  • 1